Apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G (APOBEC3G, referred to here as A3G) is a potent antiretroviral host factor against human immunodeficiency virus type 1 (HIV-1). HIV-1 viral infectivity factor (Vif ) counteracts A3G by promoting its degradation via the ubiquitin-proteasome pathway. Recent studies demonstrated that protein kinase A (PKA) phosphorylates activation-induced deaminase (AID), another member of the APOBEC3 family. A3G has two putative PKA phosphorylation residues. Here we show that PKA binds and specifically phosphorylates A3G at Thr32 in vitro and in vivo. This phosphorylation event reduces the binding of A3G to Vif and its subsequent ubiquitination and degradation, and thus promotes A3G antiviral activity. Computer-assisted structural modeling and mutagenesis studies suggest that the interaction between A3G Thr32 and Arg24 is crucial for interaction with Vif. These data imply that PKA-mediated phosphorylation of A3G can regulate the interaction between A3G and Vif.
A3G is a potent antiretroviral host factor against HIV-1. A3G is incorporated into budding virions and subsequently introduces cytidine-to-uridine mutations in the minus-strand viral DNA during reverse transcription in target cells, resulting in inhibition of HIV-1 replication [1] [2] [3] [4] . On the other hand, HIV-1 Vif counteracts the antiviral activity of APOBEC3G to enable HIV-1 to replicate in nonpermissive target cells 5 . Vif forms an E3 ubiquitin-ligase complex with ElonginB/C and Cullin5 and degrades A3G through the ubiquitin-proteasome pathway 6, 7 . Meanwhile, another APOBEC family protein, activation-induced deaminase (AID) is a B-cell specific cytidine deaminase that has a key role in somatic hypermutation (SHM) and class switch recombination (CSR), which enable diversification of immunoglobulin genes in germinal center B cells 8 . Recent studies have provided the evidence that PKA-mediated phosphorylation regulates the function of AID on CSR 9, 10 . PKA phosphorylates Thr27 and Ser38 of AID embedded in a PKA consensus phosphorylation motif, R(R)X(S/T). Phosphorylation of these residues makes AID accessible to double-stranded DNA, leading to CSR. The first PKA consensus phosphorylation site (Thr27) of AID is conserved upstream of each cytidine-deaminase domain (CDD) of A3G (29-RRNT-32, 215-RHET-218) (Fig. 1a) . These findings raise the possibility that A3G function is also regulated by PKA-mediated phosphorylation.
PKA is a key serine/threonine kinase downstream of the cyclic AMP signaling pathway. In an unstimulated state, PKA exists in the cytoplasm as an inactive heterotetramer holoenzyme consisting of two regulatory subunits and two catalytic subunits. Following stimulation, which elevates the intracellular cAMP concentration, cAMP binds to the regulatory subunits; subsequently, the catalytic subunits dissociate to become catalytically active, and they are able to phosphorylate serine or threonine in a specific motif R(R)X(S/T) on substrate proteins. The most common motif in PKA physiological substrates is RRXS, followed by RRXT, and then RXX(S/T) 11 . cAMP and PKA signaling have been shown to play an important role in the HIV-1 life cycle and AIDS pathogenesis. cAMP levels and PKA kinase activity of T cells among AIDS patients are known to be elevated 12 and affect host factors as well as viral factors. In host factors, PKA signals upregulate expression of a chemokine receptor, CXCR4 (ref. 13) , and downregulate expression of another chemokine receptor, CCR5 (refs. 14,15) . In viral factors, several groups have reported that PKA signals regulate the transcriptional activity of HIV-1 long terminal repeat 16, 17 . PKA phosphorylates viral capsid 18 and Nef proteins 19 , which results in the increasing spread of HIV-1. PKA is also involved in T-cell dysfunction of HIV-1-infected patients 20 , and PKA antagonist was able to restore T-cell function in these patients by in vitro assays 12 .
In this study, we examined whether human PKA can phosphorylate A3G and regulate its function. We show that PKA physically binds and specifically phosphorylates A3G at Thr32 and that PKA influences its antiretroviral activity.
RESULTS
PKA specifically phosphorylates A3G in vitro and in vivo First, we tested whether A3G physically interacts with human PKA catalytic subunit a type I (PKACA) by co-transfecting 293T cells with expression vectors for hemagglutinin (HA)-A3G and Flag-PKACA. Immunoblot analysis showed that Flag-PKACA was coprecipitated with HA-A3G (Fig. 1b, lane 3) , but not in cells transfected with Flag-PKACA alone (lane 1) or HA-A3G alone (lane 2). We further examined whether A3G interacts with endogenous PKACA by immunoprecipitation of green fluorescent protein (GFP)-A3G from U937 cells stably expressing GFP or GFP-A3G. Endogenous PKACA was coprecipitated with GFP-A3G (Fig. 1c, lane 2 ), but not with GFP. To assess whether A3G can serve as a target for PKA-mediated phosphorylation, we performed in vitro phosphorylation assays using recombinant PKACA and GST-Flag-A3G proteins. The results showed that A3G was phosphorylated by PKACA in a dose-dependent manner (Fig. 1d, lanes 3  and 4) , but not in the absence of PKACA (lane 1) or ATP (lane 2).
Whereas AID carries two PKA phosphorylation sites (Thr27 and Ser38) located upstream of the CDD, A3G possesses two putative target residues located upstream of each CDD: Thr32 and Thr218 (Fig. 1a) . To examine whether A3G was phosphorylated by PKA in vivo and which putative site was phosphosylated, we performed in vivo phosphorylation assays with alanine-substitution mutants. Overexpression of PKACA induced phosphrylation of wild-type A3G and the mutant T218A (Fig. 1e, lanes 7 and 9) , but not of T32A and T32A T218A (lanes 8 and 10), demonstrating that Thr32 is a crucial residue. Coimmunoprecipitaed Flag-PKACA was detected in each lane (below, lanes 7-10), suggesting that PKACA could bind not only to wild-type A3G but to all the mutants. Furthermore, treatment of transfected 293T cells with the PKA-specific activator, dibutyryl cAMP (dB-cAMP) induced the phosphorylation of A3G in a dosedependent manner (Fig. 1f, lanes 2 and 3) , an effect that was completely blocked by pretreatment with the PKA-specific inhibitor H89 (lanes 4 and 5), suggesting that this modification is specific. Treatment of monocytic U937 cells stably expressing A3G with dB-cAMP also induced the phosphorylation of A3G, which was completely blocked by H89 (data not shown). These indicate that activation of endogenous PKA signals can also induce A3G phosphorylation at Thr32. Taken together, these data indicate that PKA binds and specifically phosphorylates A3G at Thr32.
Antiviral activity of phosphorylated A3G
We next examined the antiviral activity of phosphorylated A3G using VSV-G-pseudotyped NL4-3 luciferase reporter viruses. In the absence of PKA signals, A3G and its mutants showed similar antiviral activity against both wild-type and Dvif viruses (Fig. 2a) . Cellular expression and virion-incorporation levels of A3G and its mutants were also similar (Fig. 2b) , suggesting that substitution of threonine to alanine at positions 32 or 218 did not influence virion incorporation or antiviral activity of A3G without PKA signals. In contrast, when PKACA was overexpressed, wild-type A3G and T218A showed more potent antiviral activity than nonphosphorylated mutants (T32A and T32A T218A) against wild-type viruses (Fig. 2c, gray bars) , whereas they showed similar antiviral activity against Dvif viruses (white bars), suggesting that phosphorylation of A3G did not affect antiviral activity itself. Cellular expression and virion-incorporation levels of wild-type A3G and the T218A mutant were less reduced by Vif than those of nonphosphorylated mutants (T32A and T32A T218A; T218A mutant showed more potent antiviral activity only against the wild-type viruses than did the nonphosphorylated mutants because they are more resistant to neutralization by Vif (Fig. 2c,d ). Virionincorporated A3G was also detected using an anti-RRXT antibody (lanes 3 and 7), suggesting that phosphorylated A3G was incorporated into virions. Additionally, PKACA was also incorporated into virions, as reported previously 18 ( Fig. 2d , 'Anti-Flag (PKACA)'). When transfected 293T cells were treated with dB-cAMP, wild-type A3G also showed more potent antiviral activity than the T32A mutant only against the wild-type viruses, although to a lesser extent than observed in assays with PKACA overexpression (Fig. 2e) . These findings suggest that PKA-mediated phosphorylation of A3G affects the neutralization of antiviral activity of A3G by Vif.
Antiviral activity of phosphomimetic A3G mutants
To further investigate the importance of PKA-mediated phosphorylation in the antiviral activity of A3G, we made phosphomimetic mutants (which mimicked phosphorylation by substituting threonine with aspartic acid; Fig. 3a ) and examined their antiviral activity using VSV-G-pseudotyped luciferase reporter viruses. In contrast to nonphosphorylation mutants, phosphomimetic mutants of the first PKA phosphorylation site (T32D and T32D T218D) showed more potent antiviral activity against wild-type viruses than wild-type A3G and T218D even without PKA signals, whereas they showed similar antiviral activity against Dvif viruses (Fig. 3b) , again suggesting that these mutations did not affect the A3G's antiviral activity itself. Cellular expression levels of the T32D and T32D T218D mutants were less reduced by Vif than those of wild-type A3G and T218D (Fig. 3c , lower middle, lanes 6 and 10, as compared with lanes 4 and 8). Consequently, the T32D and T32D T218D mutants were more incorporated into wild-type virions than wild-type A3G and T218D (Fig. 3c , above, lanes 6 and 10 as compared with lanes 4 and 8).
To test the possibility that T32D is resistant to Vif-induced degradation, Vif sensitivity was analyzed by transfecting 293T cells with expression vectors for HA-A3G wild type and T32D together with increasing amounts of Vif expression vectors. Cell lysates were subjected to immunoblot with the indicated antibodies (Fig. 3d) . Cellular expression levels of wild-type A3G were downregulated to 38% in response to Vif expression, but expression of T32D remained at 73%, even in the presence of Vif (Fig. 3d , top blot and graph). Coimmunoprecipitation assays showed that the T32D and T32D T218D mutants bound less efficiently to Vif than wild-type A3G and T218D (Fig. 3e , above, lanes 4 and 6, as compared with lanes 3 and 5). Finally, in vivo ubiquitination assays showed that ubiquitination of T32D and T32D T218D by Vif was clearly reduced as compared with that of wild-type A3G and T218D (Fig. 3f , above, lanes 5 and 7, as compared with lanes 4 and 6), indicating that phosphomimetic A3G mutants of Thr32 have more potent antiviral activity only against wild-type viruses because these mutants bound to Vif with less efficiency, were less ubiquitinated by Vif and were more resistant to Vif-induced degradation. Taken together with previous data, this suggests that PKA-mediated phosphorylation antagonizes Vif-induced degradation of A3G.
Phosphorylation affects interaction between Thr32 and Arg24 A3G consists of two tandem domains, the N-terminal and C-terminal domains. Thr32 is located in the N-terminal domain, which has been suggested to be crucial for interaction with Vif and for virion incorporation of A3G [21] [22] [23] [24] [25] , although a complete picture of the interacting sites and molecules remains unclear. To obtain structural insights into the mechanisms by which Thr32 controls sensitivity to Vif-mediated neutralization, we conducted computer-assisted molecular modeling of the A3G N-terminal domain. The models constructed in this study included wild-type A3G, phosphorylated A3G (p-A3G), T32A and T32D. Thermodynamically optimized threedimensional structures showed that the A3G N-terminal domain consists of a packed core structure with five b-strands and six a-helices, arranged from the N terminus to the C terminus in an a1-b1-b2/b2¢-a2-b3-a3-b4-a4-b5-a5-a6 configuration (Fig. 4a) . The configuration was the same among the four models and similar to that of the recently reported A3G catalytic C-terminal domain structure 26 . Asp128, a critical determinant of species-specific sensitivity of A3G to Vif [21] [22] [23] [24] , is located on the exposed b4-a4 loop (Fig. 4a-d, blue) , as predicted by modeling based on the Escherichia coli cytidine deaminase 24 . Similarly, residues Tyr124 to Trp127, which contribute to virion incorporation, and Asp128 to Asp130, which contribute to interaction with Vif 25 , are also exposed on the same protein surface (Fig. 4a-d, yellow and blue, respectively) .
In the models, the amino acid at position 32 is located at the top of the b1 strand (Fig. 4a-d, red) , on the same protein surface with residues 124-130 but separate from them. Consistently, no obvious differences in the conformations of these amino acids were detected among the models. Notably, the amino acid at position 32 is near Arg24 on the a1-b1 loop (Fig. 4a-d, orange) . Arg24 is highly exposed to solvent and available to bind to negatively charged molecules, and its side chain is part of the same surface as that formed by residues 124-130 (Fig. 4a-d) . The side chain of the amino acid at position 32 protrudes toward that of Arg24 in such a way that it could affect the movement of the Arg24 side chain. The hydrogen bonds between Arg24 and the side chains of the amino acids at position 32 are different among the models: Thr32 is predicted to form a single hydrogen bond with Arg24 (Fig. 4e) , whereas phosphorylated Thr32 forms two hydrogen bonds (with oxygen atoms supplied by the phosphate group) (Fig. 4f) . T32A resulted in a loss of hydrogen bonds (Fig. 4g) . Finally, T32D, which has similar effects on Vif interaction as phosphorylation (Fig. 3) , also formed two hydrogen bonds, with oxygen atoms supplied by the negatively charged side chain (Fig. 4h) .
We also constructed models of the A3G N-terminal domain using the recently reported NMR structure of the A3G C-terminal domain (PDB 2JYW 26 ) as a template. This procedure generated structural models similar to those obtained using the APOBEC2 crystal structure ( Supplementary Fig. 1 online) . Phosphorylation or substitution of the amino acid at position 32 similarly influenced the formation of hydrogen bonds with Arg24 ( Supplementary Figs. 2a-d online) . However, because of the intrinsic 9-residue N-terminal deletion of the A3G C-terminal domain compared with the A3G N-terminal domain, an a-helix structure at the N terminus was missing when the NMR structure of the A3G C-terminal domain was used as a template for modeling ( Supplementary Fig. 1 ).
Importance of Arg24 for Vif binding and virion incorporation
Because our structural models suggest that the interaction between Thr32 and Arg24 in A3G has an important role in virion incorporation and interaction with Vif, we examined the antiviral activity of the A3G mutants R24A and R24A T32D. Cellular expression levels of these mutants were adjusted by transfection with more plasmid DNA. R24A T32D was less resistant to Vif than T32D (Fig. 5, below 98%, respectively). Moreover, R24A substitution restored the binding of T32D to Vif (Fig. 5c , above, lane 6 compared with lane 5). Accordingly, infectivity assays showed that R24A T32D lost the potent antiviral activity of T32D against wild-type viruses (Fig. 5a) , supporting the hypothesis that the interaction between Thr32 and Arg24 has a crucial role in interaction with Vif. In addition, the R24A and R24A T32D mutants showed impaired antiviral activity even against Dvif viruses, because they were less efficiently incorporated into virions (Fig. 5b, above, lanes 5 and 9 ; incorporation rates were 28% and 10%, respectively). Therefore, these data suggest that Arg24 might also have an important role in virion incorporation.
DISCUSSION
In this study, we show that PKA specifically phosphorylates Thr32 on A3G and that PKA-mediated phosphorylation of A3G confers resistance to Vif-induced ubiquitination and degradation. We also show that the interaction between Thr32 and Arg24 has an important role in regulating A3G's interaction with Vif.
We first demonstrated the physical interaction between A3G and PKACA by immunoprecipitation asssays, although we cannot exclude the possibility that this interaction is indirect, through binding to PKA regulatory subunits. We also showed that PKA can phosphorylate A3G in vitro and in vivo. PKACA is sufficient to phosphorylate A3G in vitro. In vivo, PKACA overexpression or activation of endogenous PKA induced by dB-cAMP can promote the phosphorylation of A3G, suggesting that PKA specifically phosphorylates A3G in vivo. We also showed that virion-incorporated A3G is phosphorylated by PKA (Fig. 2d) . PKA is anchored by AKAP and mainly exists at the plasma membrane or subcellular organelles. On the other hand, A3G resides in RNA-processing bodies in the cytoplasm. Where does PKA phosphorylate A3G? In HIV-1 infected cells, A3G is recruited into the plasma membrane through the HIV-1 Gag interaction. PKA might therefore target A3G during virion budding. Another possibility is that virion-incorporated PKA might target A3G in virions, because PKA has been shown to be incorporated into virions 18 (Fig. 2d) . Further study is necessary to clarify this issue.
We next demonstrated that PKA signals increase the antiviral activity of A3G against wild-type viruses, because cellular expression and virion-incorporation levels of A3G are less reduced by Vif in the presence of PKA. Our data clearly indicate that PKA regulates the functional interaction between A3G and Vif, but not A3G antiviral activity per se, although we cannot completely exclude the possibility that PKA might regulate other physiological functions of A3G. In the case of AID, the T27A and S38A mutants lost deaminase activity only on double-stranded DNA, whereas they showed similar deaminase activity on single-stranded DNA, suggesting that phosphorylation by PKA does not affect deaminase activity itself, but instead induces conformational changes in AID, enabling it to access double-stranded DNA 9 .
We investigated the mechanisms by which A3G phosphorylation confers Vif resistance. Phosphorylation of A3G at Thr32 reduces binding to Vif and A3G's subsequent ubiquitination, resulting in a Vif-resistant phenotype. Comparison of the structural models for the A3G N-terminal domain revealed that Thr32 interacts with Arg24, and its phosphorylation or substitution with a negatively charged amino acid would stabilize this interaction (Fig. 4e-h ). The models suggest that the side chain of Arg24 in phosphorylated A3G or T32D mutant has a more rigid conformation than it does in dephosphorylated A3G or T32A mutant, because of increased Coulomb interactions with the negatively charged side chains. APOBEC2 has a corresponding loop to the a1-b1 loop where Arg24 is located, termed the L1 loop, whose basic amino acids are directly involved in joining inner domains through head-to-head interactions during tetramer formation 27 . Notably, the A3G a1-b1 loop has additional basic amino acids, Arg29 and Arg30, forming a positively charged protein surface. These observations suggest that the A3G a1-b1 loop is available to have a direct role in binding to the negatively charged surface of other molecules. If this were the case, the degrees of conformational freedom of Arg24 would crucially influence interaction efficiency and specificity.
As expected, the substitution of Arg24 to alanine abrogates Vif resistance of the T32D mutant and also impairs the ability for virion incorporation to some extent. Structural modeling of the R24A mutant protein showed that the hydrogen bond between residues 32 and 24 was missing, whereas no changes in the main chain structure were induced in other regions ( Supplementary Fig. 2e ). The data suggest that the R24A substitution mainly influences the degrees of conformational freedom and positively charged status of the protein surface around residue 24, although we cannot exclude the possibility that the R24A mutation induces allosteric changes in A3G conformation. Taken together, our data suggest that the amino acid at position 32 controls conformational changes of Arg24, which in turn influence A3G's interaction with Vif and molecules for virion incorporation.
Although PKA-mediated phosphorylation renders A3G resistant to Vif-induced neutralization, in fact, the pathology of most HIV-1-infected patients progresses to AIDS. A recent study reported that naturally occurring Vif point mutants with suboptimal anti-A3G activity induce drug resistance-associated mutations in the HIV-1 provirus 28 . In other words, the imbalance between the antiviral activity of A3G and the anti-A3G activity of Vif could determine HIV-1 genome diversity. Our data suggest that the phosphorylated A3G or T32D mutants are not fully resistant to Vif (Figs. 2c and 3b ), but they might cause this balance to be disturbed. PKA-mediated phosphorylation of A3G might contribute to genetic diversity of HIV-1. Further study will be required to clarify this issue. Finally, PKA-mediated phosphorylation regulates the functional interaction between A3G and Vif, which might be a target for new strategies to control HIV-1 replication.
METHODS
Plasmids and cell lines. We constructed an expression vector for HA-tagged human A3G, pcDNA3/HA-A3G, as previously described 29 . We generated expression vectors for A3G mutants (T32A, T218A, T32D, T218D, R24A) by QuickChange XL Site Directed Mutagenesis Kit (Stratagene) using pcDNA3/HA and pDON/EGFP vectors 4 . We amplified human PKACA by PCR and cloned it into pcDNA3/Flag. pNLA1-43Vif (a gift from H. Akari) was constructed by inserting a Vif fragment from NL4-3 into the subgenomic expression vector pNL-A1 (ref. 30) , and this expressed all HIV-1 proteins except for gag, pol, and vpr products. We constructed pNL43/DEnv-Luc and pNL43/DEnvDvif-Luc as previously described 4 . HEK293T and M8166 cells were maintained as previously described 4 . We established U937/GFP and U937/GFP-A3G cells, expressing GFP and GFP-tagged A3G, respectively, by retroviral transduction of GFP and GFP-A3G, respectively, and maintained them with RPMI1640 containing 10% (v/v) FCS.
In vitro phosphorylation assays. We incubated purified GST-Flag-tagged A3G prepared with a baculovirus expression system and recombinant PKACA (Upstate Cell Signaling Solutions) in an appropriate buffer (20 mM Tris, pH 7.5, 10 mM MgCl 2 , 1 mM DTT, 25 mM glycerophosphate, 0.1 mM NaVO 4 , 1 mM ATP, 1 mM cAMP) at 30 1C for 30 min, and analyzed them by immunoblot with phospho-(Ser/Thr) PKA substrate antibody (anti-RXXT) (Cell Signaling Technology).
In vivo phosphorylation assays. We transfected HEK293T cells with expression vectors for GFP-A3G, its mutants, and/or Flag-PKACA by the calcium phosphate method. At 36 h after transfection, we lysed cells in lysis buffer (25 mM HEPES, pH7.4, 150 mM NaCl, 1 mM MgCl 2, 0.5% (v/v) TritonX-100, 10% (v/v) glycerol, 25 mM b-glycerophosphate and 100 mM NaVO 4 ) and immunoprecipitated GFP-A3G with anti-GFP mAb and Protein A Sepharose beads (Amersham Biosciences) at 4 1C. We washed the beads with lysis buffer and analyzed them by immunoblot with Phospho-PKA Substrate Rabbit mAb (100G7) (anti-RRXT; Cell Signaling Technology) or anti-Flag mAb (M2) (Sigma-Aldrich). We also treated transfected HEK293T cells with 50 mM H89 (Sigma-Aldrich) for 2 h, followed by 100 mM or 500 mM dibutyryl cAMP (Sigma-Aldrich) for 4 h.
Infectivity assays with luciferase reporter viruses. We prepared Luciferase reporter viruses with or without Vif by co-transfection of pNL43/DEnv-Luc (wild type) or pNL43/DEnvDvif-Luc(vif) plus pVSV-G, together with expression vectors for A3G, its mutants, and/or Flag-PKACA by the calcium phosphate method 4 . We collected viruses in the supernatants 48 h after transfection and measured virus titers with an enzyme-linked immunosorbent assay kit for the p24 antigen (RETRO-TEK, ZeptoMetrix). We challenged an adjusted amount of viruses to target M8166 cells. At 24 h after infection, we lysed the cells in passive lysis buffer (Promega) and measured their luciferase activity with a Luminometer (EG & G Berthold). We presented values as percent infectivity relative to the value of wild-type or Dvif virus without the expression of A3G. In Figures 2d and 5b, band intensities were quantified using Image J software (http://rsb.info.nih.gov/ij/). Reduction rates of A3G by Vif were calculated as the ratio of A3G levels with Vif to those without Vif in cell lysates, normalized by the amounts of b-actin intensity. Additionally, in Figure 5b , virion-incorporation rates were calculated as the ratio of A3G levels in virions to those in cell lysates, normalized by the amounts of p24 and b-actin intensity, respectively.
Co-immunoprecipitation assays. To see the A3G-Vif interaction in vivo, we performed immunoprecipitation assays as described previously 4 . We transfected HEK293T cells with expression vectors for HA-A3G, its mutants, and Vif as indicated. At 36 h after transfection, we lysed cells in lysis buffer and immunoprecipitated complexes with anti-HA mAb (12CA5; F. HoffmannLa Roche) and Protein A Sepharose beads at 4 1C. We washed the beads with lysis buffer and analyzed them by immunoblot with anti-HA or anti-Vif mAbs (#319; a gift from M. Malim through the AIDS Research and Reference Reagent Program) 31 .
In vivo ubiquitination assays. We transfected HEK293T cells with expression vectors for A3G, its mutants, Vif and Flag-tagged ubiquitin (Flag-Ub) as indicated. We treated cells with 10 mM MG132 for 6 h before harvest. At 48 h after transfection, we lysed cells in lysis buffer and immunoprecipitated them with anti-HA mAb and Protein A Sepharose beads at 4 1C. We washed the beads with lysis buffer and analyzed them by immunoblot with anti-HA, anti-Flag and anti-Vif mAbs.
Molecular modeling of the APOBEC3G N-terminal domain. We took the crystal structure of APOBEC2 at a resolution of 2.50 Å (PDB 2NYT 27 ). APOBEC2 belongs to the APOBEC family and has cytidine-deaminase activity, as does A3G 32, 33 . The sequence identity of A3G (Genbank NM_021822) N-terminal domain and APOBEC2 (PDB 2NYT; chain B) is B29.5%. These functional and sequence similarities are sufficient to construct models with an r.m.s. deviation of B1.5 Å for the main chain between the predicted and actual structures 34 . To minimize misalignments of the target sequence, the A3G N-terminal domain and the template sequence, APOBEC2, we used the multiple sequence alignment method with the sequences of APOBEC3A (Genbank NM_145699), APOBEC3C (Genbank NM_014508) and APOBEC3F (Genbank NM_145298). We generated multiple sequence alignments using 'MOE-Align' in the Molecular Operating Environment (MOE; Chemical Computing Group). We constructed three-dimensional models of the A3G N-terminal domain by the homology modeling technique using 'MOEHomology' in MOE as previously described 35, 36 . We optimized the threedimensional structure thermodynamically by energy minimization using MOE and an AMBER99 force field 37 . We further refined the physically unacceptable local structure of the optimized three-dimensional model on the basis of evaluation by the Ramachandran plot using MOE. We constructed the three-dimensional model of A3G with phosphorylated Thr32 by adding the phosphate group to the side chain of Thr32 in the three-dimensional model of A3G using 'Molecular Builder' in MOE and by energy minimization. We also constructed the three-dimensional models of A3G T32A or T32D by the same method as the A3G model. Note: Supplementary information is available on the Nature Structural & Molecular Biology website.
